nitrofurantoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
NO2 - derivatives	1949	67-20-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nitrofurantoin sodium nitrofurantoin furadantin furadantoin nitrofurantoin, macrocrystalline nitrofurantoin monohydrate	A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression. Molecular weight: 238.16 Formula: C8H6N4O5 CLOGP: -0.47 LIPINSKI: 0 HAC: 9 HDO: 1 TPSA: 120.73 ALOGS: -2.76 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nitrofurantoin sodium
nitrofurantoin
furadantin
furadantoin
nitrofurantoin, macrocrystalline
nitrofurantoin monohydrate

A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.

Molecular weight: 238.16
Formula: C8H6N4O5
CLOGP: -0.47
LIPINSKI: 0
HAC: 9
HDO: 1
TPSA: 120.73
ALOGS: -2.76
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.08 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	47 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	24 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	87 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.57 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.17 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.97 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 6, 1953	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	364.22	10.85	626	40008	264058	63184330
Autoimmune hepatitis	205.36	10.85	103	40531	8407	63439981
Jaundice	152.58	10.85	136	40498	29115	63419273
Drug ineffective	134.01	10.85	295	40339	1044470	62403918
Infusion related reaction	98.23	10.85	19	40615	245502	63202886
Contraindicated product administered	95.66	10.85	13	40621	217635	63230753
Pulmonary toxicity	95.41	10.85	65	40569	9390	63438998
Drug hypersensitivity	94.25	10.85	421	40213	310266	63138122
Cystitis	92.82	10.85	143	40491	54848	63393540
Synovitis	87.50	10.85	9	40625	186909	63261479
Therapeutic product effect decreased	81.51	10.85	13	40621	193174	63255214
Swollen tongue	80.17	10.85	105	40529	34695	63413693
Hand deformity	79.17	10.85	6	40628	159451	63288937
Glossodynia	77.85	10.85	11	40623	178865	63269523
Oesophageal spasm	75.93	10.85	38	40596	3085	63445303
Drug-induced liver injury	74.14	10.85	109	40525	40113	63408275
Oesophageal pain	69.84	10.85	38	40596	3663	63444725
Systemic inflammatory response syndrome	69.79	10.85	44	40590	5577	63442811
Lip swelling	65.85	10.85	90	40544	30973	63417415
Heart sounds	63.72	10.85	24	40610	972	63447416
Rheumatoid arthritis	62.47	10.85	43	40591	253776	63194612
Pulmonary fibrosis	62.28	10.85	100	40534	39709	63408679
Systemic lupus erythematosus	62.07	10.85	28	40606	208890	63239498
Prolonged expiration	61.49	10.85	24	40610	1072	63447316
Wound	58.56	10.85	16	40618	163247	63285141
Arthropathy	57.48	10.85	40	40594	234752	63213636
Change of bowel habit	57.22	10.85	28	40606	2165	63446223
Interstitial lung disease	57.18	10.85	124	40510	61784	63386604
Rectal polyp	55.25	10.85	23	40611	1216	63447172
Urine odour abnormal	53.06	10.85	39	40595	6350	63442038
Off label use	50.06	10.85	242	40392	674220	62774168
Bladder disorder	47.44	10.85	42	40592	8904	63439484
Drug intolerance	47.24	10.85	78	40556	308583	63139805
Treatment failure	46.00	10.85	36	40598	199007	63249381
Pericarditis	45.15	10.85	14	40620	131565	63316823
Lymphoedema	45.04	10.85	46	40588	11646	63436742
Joint swelling	42.91	10.85	91	40543	327575	63120813
Malaise	42.72	10.85	430	40204	415524	63032864
Intestinal haemorrhage	40.13	10.85	27	40607	3820	63444568
Appetite disorder	38.08	10.85	34	40600	7287	63441101
Multiple sclerosis	37.81	10.85	61	40573	24311	63424077
Discomfort	37.75	10.85	31	40603	167343	63281045
Cardiac murmur	36.80	10.85	46	40588	14506	63433882
Swelling	36.44	10.85	76	40558	275302	63173086
Rales	35.13	10.85	42	40592	12655	63435733
Tinnitus	34.78	10.85	73	40561	35555	63412833
Hallucination	34.76	10.85	95	40539	54722	63393666
Depressive symptom	33.97	10.85	25	40609	4077	63444311
Musculoskeletal stiffness	33.84	10.85	41	40593	184577	63263811
Respiration abnormal	33.77	10.85	30	40604	6387	63442001
Sensitisation	33.50	10.85	23	40611	3363	63445025
Alopecia	33.30	10.85	108	40526	337428	63110960
Hepatic enzyme increased	32.96	10.85	49	40585	202279	63246109
Dysuria	32.78	10.85	69	40565	33669	63414719
Hydronephrosis	32.38	10.85	37	40597	10625	63437763
Liver function test abnormal	32.06	10.85	85	40549	48096	63400292
Hepatic fibrosis	31.93	10.85	23	40611	3629	63444759
Swelling face	31.65	10.85	101	40533	63374	63385014
Irritable bowel syndrome	31.63	10.85	7	40627	82405	63365983
Frustration tolerance decreased	31.58	10.85	30	40604	6958	63441430
Urine abnormality	31.47	10.85	30	40604	6989	63441399
Folliculitis	31.34	10.85	4	40630	70313	63378075
Urosepsis	31.00	10.85	48	40586	18476	63429912
Muscle injury	30.94	10.85	3	40631	65342	63383046
Tubulointerstitial nephritis	29.77	10.85	49	40585	19854	63428534
Catarrh	29.49	10.85	16	40618	1533	63446855
Hypersensitivity pneumonitis	28.61	10.85	19	40615	2631	63445757
Drug abuse	28.16	10.85	6	40628	72512	63375876
Gallbladder disorder	27.66	10.85	46	40588	18796	63429592
Injection site discomfort	27.10	10.85	23	40611	4607	63443781
Hiccups	26.54	10.85	17	40617	2214	63446174
Abdominal discomfort	26.18	10.85	111	40523	320774	63127614
Urinary incontinence	26.06	10.85	61	40573	31953	63416435
Psoriatic arthropathy	26.03	10.85	13	40621	91507	63356881
Costovertebral angle tenderness	26.00	10.85	7	40627	92	63448296
Burns second degree	25.86	10.85	16	40618	1962	63446426
Product use issue	25.81	10.85	65	40569	220455	63227933
Polyp	25.74	10.85	26	40608	6495	63441893
Furuncle	25.59	10.85	26	40608	6540	63441848
Febrile neutropenia	25.41	10.85	23	40611	118426	63329962
Peripheral coldness	25.40	10.85	35	40599	12130	63436258
Flank pain	25.35	10.85	41	40593	16369	63432019
Eosinophilia	25.03	10.85	49	40585	22707	63425681
Injury	25.00	10.85	103	40531	73144	63375244
Steroid dependence	24.93	10.85	15	40619	1749	63446639
Chromaturia	24.79	10.85	41	40593	16676	63431712
Acute hepatic failure	24.60	10.85	43	40591	18284	63430104
Pyelonephritis	24.24	10.85	42	40592	17736	63430652
Multiple sclerosis relapse	24.04	10.85	77	40557	48401	63399987
Cystitis bacterial	23.91	10.85	8	40626	228	63448160
Therapeutic product effect incomplete	23.73	10.85	27	40607	125029	63323359
Pollakiuria	23.58	10.85	54	40580	27883	63420505
Proctalgia	23.46	10.85	24	40610	6086	63442302
Mass	23.04	10.85	36	40598	13964	63434424
Amblyopia	22.83	10.85	8	40626	263	63448125
Drug reaction with eosinophilia and systemic symptoms	22.82	10.85	60	40574	33776	63414612
Arthralgia	22.79	10.85	244	40390	569466	62878922
Sinusitis	22.69	10.85	72	40562	226581	63221807
Hyperhidrosis	22.66	10.85	132	40502	107704	63340684
Emotional distress	22.24	10.85	58	40576	32491	63415897
Cholecystitis chronic	21.92	10.85	30	40604	10331	63438057
Atrioventricular block first degree	21.68	10.85	25	40609	7248	63441140
Vascular device infection	21.58	10.85	25	40609	7287	63441101
Liver transplant	21.35	10.85	15	40619	2276	63446112
Stress	21.02	10.85	92	40542	67075	63381313
Cystitis interstitial	21.00	10.85	13	40621	1595	63446793
Postoperative wound infection	20.69	10.85	30	40604	10895	63437493
Neurogenic bladder	20.64	10.85	17	40617	3268	63445120
Nail infection	20.05	10.85	15	40619	2508	63445880
Knee arthroplasty	20.02	10.85	5	40629	54201	63394187
Sleep apnoea syndrome	19.99	10.85	52	40582	29081	63419307
Therapy non-responder	19.82	10.85	12	40622	75889	63372499
Impaired healing	19.61	10.85	22	40612	102520	63345868
Duodenal ulcer	18.79	10.85	24	40610	7732	63440656
Adverse event	18.61	10.85	10	40624	67549	63380839
Fracture displacement	18.54	10.85	11	40623	1250	63447138
Hypopnoea	18.47	10.85	17	40617	3789	63444599
Infection	18.23	10.85	80	40554	229093	63219295
Acute febrile neutrophilic dermatosis	17.87	10.85	15	40619	2959	63445429
Hepatic cirrhosis	17.85	10.85	45	40589	24689	63423699
Pseudophaeochromocytoma	17.84	10.85	5	40629	77	63448311
Hepatitis	17.77	10.85	61	40573	39727	63408661
Musculoskeletal discomfort	17.75	10.85	37	40597	17930	63430458
Hepatic necrosis	17.72	10.85	20	40614	5667	63442721
Colour blindness acquired	17.72	10.85	5	40629	79	63448309
Urinary tract infection bacterial	17.67	10.85	19	40615	5103	63443285
Death	17.62	10.85	154	40480	374227	63074161
Kidney infection	17.61	10.85	43	40591	23133	63425255
Nephrolithiasis	17.57	10.85	63	40571	41921	63406467
Abdominal pain	17.39	10.85	274	40360	293182	63155206
Rash macular	17.38	10.85	43	40591	23321	63425067
Neutropenia	17.23	10.85	56	40578	174949	63273439
Hepatitis acute	17.21	10.85	25	40609	9095	63439293
Weight decreased	16.61	10.85	259	40375	276539	63171849
Anhedonia	16.39	10.85	27	40607	10947	63437441
Chronic hepatitis	16.35	10.85	9	40625	887	63447501
Ill-defined disorder	16.23	10.85	17	40617	81738	63366650
Blister	16.18	10.85	37	40597	129777	63318611
Needle issue	16.13	10.85	26	40608	10350	63438038
Abdominal rigidity	16.01	10.85	12	40622	2012	63446376
Pyrexia	15.99	10.85	404	40230	470074	62978314
Vision blurred	15.86	10.85	107	40527	91817	63356571
Weight increased	15.74	10.85	100	40534	260692	63187696
Pulmonary embolism	15.68	10.85	128	40506	116556	63331832
Bone disorder	15.60	10.85	39	40595	21287	63427101
Peripheral swelling	15.53	10.85	103	40531	265839	63182549
Lower urinary tract symptoms	15.43	10.85	4	40630	45	63448343
Tendinous contracture	15.34	10.85	5	40629	131	63448257
Oesophageal cancer metastatic	15.31	10.85	5	40629	132	63448256
Subacute cutaneous lupus erythematosus	15.20	10.85	13	40621	2630	63445758
Jaundice cholestatic	15.18	10.85	21	40613	7303	63441085
Agitation	15.15	10.85	77	40557	59680	63388708
Eosinophilic pleural effusion	15.11	10.85	4	40630	49	63448339
Haematuria	15.09	10.85	47	40587	29110	63419278
Blood cholesterol increased	15.08	10.85	23	40611	94009	63354379
Productive cough	15.02	10.85	80	40554	63128	63385260
Overdose	15.00	10.85	32	40602	115046	63333342
Depressed mood	14.89	10.85	58	40576	40133	63408255
Escherichia urinary tract infection	14.69	10.85	27	40607	11935	63436453
Retroperitoneal fibrosis	14.67	10.85	6	40628	303	63448085
Ureteric obstruction	14.60	10.85	11	40623	1859	63446529
Injection site mass	14.59	10.85	35	40599	18621	63429767
Helicobacter infection	14.58	10.85	23	40611	92762	63355626
Angioedema	14.47	10.85	65	40569	47900	63400488
Therapeutic response decreased	14.36	10.85	11	40623	61514	63386874
Anaemia	14.11	10.85	120	40514	293310	63155078
Intentional overdose	14.07	10.85	16	40618	74136	63374252
Cough	13.96	10.85	264	40370	292479	63155909
Nightmare	13.94	10.85	35	40599	19159	63429229
Traumatic lung injury	13.88	10.85	10	40624	1579	63446809
Cholelithiasis	13.61	10.85	60	40574	43865	63404523
Thyroid disorder	13.57	10.85	30	40604	15132	63433256
Maternal exposure during pregnancy	13.47	10.85	84	40550	219978	63228410
Bronchiectasis	13.40	10.85	31	40603	16111	63432277
Rash	13.17	10.85	460	40174	560411	62887977
Sleep disorder due to a general medical condition	13.11	10.85	26	40608	12162	63436226
Poor peripheral circulation	13.10	10.85	14	40620	3735	63444653
Hyponatraemia	13.07	10.85	119	40515	111781	63336607
Product contamination microbial	13.01	10.85	5	40629	214	63448174
Depression	13.00	10.85	187	40447	196305	63252083
Chest discomfort	12.87	10.85	117	40517	109852	63338536
Feeling abnormal	12.66	10.85	148	40486	148244	63300144
Reperfusion arrhythmia	12.49	10.85	5	40629	239	63448149
Myalgia	12.44	10.85	146	40488	146383	63302005
Bladder irritation	12.43	10.85	5	40629	242	63448146
Toxicity to various agents	12.39	10.85	100	40534	247150	63201238
Pneumonitis	12.38	10.85	50	40584	35172	63413216
Catheter site mass	12.38	10.85	3	40631	25	63448363
Acarodermatitis	12.26	10.85	8	40626	1075	63447313
Autoinflammatory disease	12.24	10.85	5	40629	252	63448136
Lichen sclerosus	12.09	10.85	8	40626	1101	63447287
Gingival pain	12.08	10.85	20	40614	8142	63440246
Rhinitis	11.93	10.85	24	40610	11342	63437046
Hip arthroplasty	11.80	10.85	8	40626	47638	63400750
C-reactive protein increased	11.79	10.85	27	40607	94680	63353708
Acute lung injury	11.73	10.85	9	40625	1562	63446826
Fluid intake reduced	11.68	10.85	13	40621	3628	63444760
Angina pectoris	11.63	10.85	44	40590	30034	63418354
Disease progression	11.58	10.85	40	40594	122718	63325670
Gastrointestinal disorder	11.57	10.85	44	40590	131195	63317193
Urinary retention	11.45	10.85	44	40590	30257	63418131
Traumatic liver injury	11.44	10.85	5	40629	298	63448090
Lung neoplasm malignant	11.43	10.85	33	40601	19600	63428788
Clostridium difficile colitis	11.43	10.85	34	40600	20535	63427853
Upper respiratory tract congestion	11.41	10.85	10	40624	2092	63446296
Wheezing	11.34	10.85	102	40532	95493	63352895
Hepatic failure	11.27	10.85	49	40585	35607	63412781
Chronic kidney disease	11.16	10.85	58	40576	45340	63403048
Organising pneumonia	11.14	10.85	16	40618	5760	63442628
Prescribed overdose	11.07	10.85	4	40630	34149	63414239
Left ventricular dysfunction	11.05	10.85	24	40610	11964	63436424
Urticaria	11.04	10.85	158	40476	165644	63282744
Chills	11.01	10.85	116	40518	113262	63335126
Tracheo-oesophageal fistula	10.95	10.85	6	40628	586	63447802
Renal pain	10.90	10.85	17	40617	6582	63441806
Hepatic encephalopathy	10.87	10.85	23	40611	11259	63437129

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	99.12	16.92	98	6318	83983	34866532
Exposure during pregnancy	73.86	16.92	35	6381	8899	34941616
Cardiac murmur	47.87	16.92	25	6391	7812	34942703
Prostatitis	32.01	16.92	17	6399	5490	34945025
Urosepsis	31.86	16.92	23	6393	12776	34937739
Protein total abnormal	30.60	16.92	8	6408	345	34950170
Pulmonary fibrosis	30.49	16.92	26	6390	18370	34932145
Pulmonary toxicity	30.26	16.92	17	6399	6130	34944385
Pulmonary valve stenosis	30.25	16.92	8	6408	361	34950154
Skin depigmentation	28.92	16.92	8	6408	428	34950087
Open reduction of fracture	28.30	16.92	6	6410	102	34950413
Burns second degree	25.15	16.92	9	6407	1120	34949395
Culture urine positive	24.55	16.92	9	6407	1201	34949314
Tendonitis	24.07	16.92	17	6399	9123	34941392
Hair colour changes	24.03	16.92	10	6406	1867	34948648
Porphyria non-acute	23.59	16.92	7	6409	482	34950033
Eye swelling	22.70	16.92	17	6399	9978	34940537
Atrial septal defect	22.42	16.92	15	6401	7377	34943138
Haematuria	22.40	16.92	36	6380	50030	34900485
Catarrh	22.37	16.92	8	6408	994	34949521
Foetal exposure during pregnancy	22.20	16.92	31	6385	38070	34912445
Breast inflammation	21.98	16.92	4	6412	29	34950486
Melanocytic naevus	21.90	16.92	10	6406	2334	34948181
Patent ductus arteriosus	21.34	16.92	11	6405	3343	34947172
Tooth injury	20.93	16.92	8	6408	1197	34949318
Steroid dependence	19.15	16.92	8	6408	1509	34949006
Hypopnoea	19.01	16.92	9	6407	2280	34948235
Cystitis	18.67	16.92	15	6401	9750	34940765
Multiple congenital abnormalities	18.47	16.92	6	6410	558	34949957
Carcinoid crisis	18.41	16.92	5	6411	250	34950265
Gastric ulcer	17.92	16.92	18	6398	15632	34934883
Blood chromogranin A increased	17.92	16.92	5	6411	276	34950239
Bone neoplasm	17.89	16.92	5	6411	278	34950237

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	391.93	11.40	579	39494	273933	79430382
Autoimmune hepatitis	185.87	11.40	99	39974	11684	79692631
Pulmonary toxicity	135.10	11.40	83	39990	12831	79691484
Jaundice	108.57	11.40	134	39939	53215	79651100
Pulmonary fibrosis	99.92	11.40	117	39956	43995	79660320
Cystitis	95.52	11.40	125	39948	52607	79651708
Drug hypersensitivity	95.08	11.40	348	39725	298568	79405747
Oesophageal spasm	93.56	11.40	42	40031	3414	79700901
Drug-induced liver injury	86.22	11.40	134	39939	65983	79638332
Swollen tongue	85.13	11.40	106	39967	42464	79661851
Oesophageal pain	82.04	11.40	41	40032	4238	79700077
Lip swelling	78.83	11.40	100	39973	40811	79663504
Drug ineffective	73.91	11.40	287	39786	1080626	78623689
Malaise	68.15	11.40	450	39623	489419	79214896
Urine odour abnormal	67.35	11.40	41	40032	6232	79698083
Heart sounds	66.23	11.40	23	40050	943	79703372
Systemic inflammatory response syndrome	63.83	11.40	50	40023	11415	79692900
Drug abuse	62.86	11.40	5	40068	162686	79541629
Infusion related reaction	60.71	11.40	20	40053	230217	79474098
Lymphoedema	60.33	11.40	50	40023	12363	79691952
Prolonged expiration	60.07	11.40	23	40050	1248	79703067
Change of bowel habit	57.57	11.40	28	40045	2729	79701586
Off label use	56.84	11.40	249	39824	906966	78797349
Bladder disorder	55.46	11.40	42	40031	9123	79695192
Synovitis	54.59	11.40	6	40067	150728	79553587
Rectal polyp	53.90	11.40	23	40050	1654	79702661
Rash	53.44	11.40	483	39590	577875	79126440
Urosepsis	49.83	11.40	64	40009	26431	79677884
Interstitial lung disease	46.26	11.40	143	39930	112457	79591858
Febrile neutropenia	44.24	11.40	31	40042	230968	79473347
Therapeutic product effect decreased	43.60	11.40	14	40059	163849	79540466
Swelling face	42.80	11.40	104	39969	71108	79633207
Tinnitus	42.06	11.40	78	39995	44255	79660060
Hypersensitivity pneumonitis	41.59	11.40	25	40048	3714	79700601
Multiple sclerosis	40.62	11.40	53	40020	22229	79682086
Contraindicated product administered	39.27	11.40	15	40058	157523	79546792
Catarrh	39.21	11.40	20	40053	2158	79702157
Hallucination	39.10	11.40	113	39960	85632	79618683
Sensitisation	39.08	11.40	23	40050	3288	79701027
Frustration tolerance decreased	38.09	11.40	31	40042	7471	79696844
Death	36.90	11.40	153	39920	566361	79137954
Liver function test abnormal	36.46	11.40	92	39981	64383	79639932
Burns second degree	35.68	11.40	20	40053	2608	79701707
Appetite disorder	35.19	11.40	30	40043	7709	79696606
Respiration abnormal	35.02	11.40	30	40043	7758	79696557
Hand deformity	33.27	11.40	6	40067	103913	79600402
Steroid dependence	32.97	11.40	19	40054	2611	79701704
Rheumatoid arthritis	32.56	11.40	34	40039	208436	79495879
Mass	32.53	11.40	42	40031	17430	79686885
Dysuria	32.32	11.40	76	39997	50875	79653440
Intestinal haemorrhage	31.47	11.40	26	40047	6400	79697915
Gallbladder disorder	30.68	11.40	43	40030	19297	79685018
Neutropenia	30.17	11.40	62	40011	287648	79416667
Toxicity to various agents	29.88	11.40	110	39963	421430	79282885
Injection site discomfort	29.78	11.40	23	40050	5143	79699172
Urine abnormality	29.73	11.40	28	40045	8191	79696124
Rales	29.57	11.40	43	40030	19958	79684357
Injury	28.70	11.40	95	39978	77401	79626914
Cardiac murmur	27.85	11.40	37	40036	15787	79688528
Furuncle	27.83	11.40	26	40047	7528	79696787
Depressive symptom	27.38	11.40	24	40049	6399	79697916
Anaemia	27.23	11.40	123	39950	444892	79259423
Hydronephrosis	26.50	11.40	38	40035	17416	79686899
Polyp	26.27	11.40	26	40047	8081	79696234
Pyelonephritis	26.11	11.40	41	40032	20347	79683968
Flank pain	25.55	11.40	40	40033	19804	79684511
Glossodynia	25.48	11.40	10	40063	103327	79600988
Amblyopia	25.42	11.40	8	40065	240	79704075
Chromaturia	25.30	11.40	46	40027	25700	79678615
Urinary tract infection bacterial	25.30	11.40	23	40050	6433	79697882
Hypopnoea	24.93	11.40	21	40052	5308	79699007
Drug reaction with eosinophilia and systemic symptoms	24.91	11.40	80	39993	64164	79640151
Treatment failure	24.23	11.40	30	40043	170456	79533859
Nail infection	24.03	11.40	15	40058	2384	79701931
Stress	23.82	11.40	91	39982	79521	79624794
Fracture displacement	23.34	11.40	12	40061	1316	79702999
Wound	23.02	11.40	15	40058	116164	79588151
Hepatic fibrosis	22.95	11.40	23	40050	7257	79697058
Multiple sclerosis relapse	22.84	11.40	63	40010	46470	79657845
Vascular device infection	22.83	11.40	27	40046	10249	79694066
Neurogenic bladder	22.65	11.40	18	40055	4194	79700121
Overdose	22.61	11.40	36	40037	184170	79520145
Feeling abnormal	22.49	11.40	147	39926	159052	79545263
Cholecystitis chronic	21.96	11.40	26	40047	9880	79694435
Culture urine positive	21.83	11.40	18	40055	4417	79699898
Vision blurred	21.69	11.40	108	39965	105790	79598525
Sleep apnoea syndrome	21.62	11.40	53	40020	36425	79667890
Arthropathy	21.37	11.40	35	40038	177076	79527239
Costovertebral angle tenderness	21.30	11.40	7	40066	242	79704073
Pericarditis	21.28	11.40	13	40060	104223	79600092
Migraine	20.67	11.40	93	39980	87400	79616915
Intentional overdose	20.56	11.40	14	40059	105946	79598369
Peripheral coldness	20.29	11.40	32	40041	15938	79688377
Proctalgia	20.14	11.40	25	40048	9976	79694339
Urinary incontinence	19.70	11.40	55	40018	40854	79663461
Postoperative wound infection	19.35	11.40	28	40045	12933	79691382
Acute hepatic failure	19.19	11.40	45	40028	30068	79674247
Hypotension	19.17	11.40	136	39937	440181	79264134
Irritable bowel syndrome	19.06	11.40	4	40069	62237	79642078
Therapeutic product effect incomplete	19.02	11.40	26	40047	141619	79562696
Tubulointerstitial nephritis	19.00	11.40	52	40021	38183	79666132
Emotional distress	18.53	11.40	53	40020	39916	79664399
Hyperhidrosis	18.51	11.40	135	39938	151357	79552958
Palpitations	17.93	11.40	117	39956	126493	79577822
Pollakiuria	17.80	11.40	50	40023	37267	79667048
Pseudophaeochromocytoma	17.76	11.40	5	40068	101	79704214
Urticaria	17.70	11.40	156	39917	185045	79519270
Femur fracture	17.67	11.40	51	40022	38601	79665714
Cystitis interstitial	17.36	11.40	10	40063	1373	79702942
Bone disorder	17.34	11.40	33	40040	19080	79685235
Gingival pain	17.33	11.40	22	40051	8976	79695339
Cystitis bacterial	17.24	11.40	8	40065	702	79703613
Eosinophilia	17.15	11.40	56	40017	45289	79659026
Abdominal pain	16.79	11.40	282	39791	389287	79315028
Colour blindness acquired	16.72	11.40	5	40068	126	79704189
Cardio-respiratory arrest	16.60	11.40	18	40055	108492	79595823
Parosmia	16.54	11.40	19	40054	6995	79697320
Prostatitis	16.52	11.40	15	40058	4187	79700128
Musculoskeletal discomfort	16.48	11.40	33	40040	19802	79684513
Needle issue	16.35	11.40	26	40047	13042	79691273
Thyroid disorder	16.24	11.40	27	40046	14052	79690263
Tendinous contracture	16.18	11.40	5	40068	141	79704174
Poor peripheral circulation	16.18	11.40	14	40059	3669	79700646
Weight increased	16.15	11.40	78	39995	277308	79427007
Haematuria	16.13	11.40	73	40000	68763	79635552
Folliculitis	16.08	11.40	4	40069	55376	79648939
Hepatic cirrhosis	15.90	11.40	46	40027	34860	79669455
Liver transplant	15.87	11.40	15	40058	4408	79699907
Atrioventricular block first degree	15.83	11.40	25	40048	12466	79691849
Nightmare	15.78	11.40	38	40035	25823	79678492
Acute febrile neutrophilic dermatosis	15.58	11.40	14	40059	3858	79700457
Hepatitis acute	15.57	11.40	28	40045	15514	79688801
Psoriatic arthropathy	15.55	11.40	10	40063	77989	79626326
Escherichia urinary tract infection	15.27	11.40	26	40047	13799	79690516
Weight decreased	15.25	11.40	257	39816	354941	79349374
Depression	15.09	11.40	171	39902	216619	79487696
Depressed mood	14.99	11.40	56	40017	48424	79655891
Drug intolerance	14.96	11.40	75	39998	264044	79440271
Injection site mass	14.92	11.40	32	40041	20152	79684163
Bronchiectasis	14.86	11.40	34	40039	22352	79681963
Lichen sclerosus	14.69	11.40	8	40065	986	79703329
Cough	14.53	11.40	262	39811	366527	79337788
Tendonitis	14.52	11.40	35	40038	23795	79680520
Hepatitis	14.51	11.40	61	40012	55666	79648649
Sinusitis	14.50	11.40	50	40023	195451	79508864
Therapy non-responder	14.46	11.40	15	40058	92290	79612025
Lower urinary tract symptoms	14.37	11.40	5	40068	206	79704109
Chronic hepatitis	14.37	11.40	9	40064	1438	79702877
Wheezing	14.27	11.40	104	39969	116560	79587755
C-reactive protein increased	14.20	11.40	27	40046	129000	79575315
Abdominal rigidity	14.10	11.40	12	40061	3076	79701239
Nail disorder	14.04	11.40	23	40050	11829	79692486
Exostosis	13.95	11.40	28	40045	16830	79687485
Porphyria non-acute	13.84	11.40	7	40066	742	79703573
Pruritus	13.62	11.40	276	39797	394372	79309943
Pulmonary embolism	13.61	11.40	139	39934	171515	79532800
White blood cells urine positive	13.56	11.40	16	40057	6059	79698256
Suicide attempt	13.54	11.40	13	40060	82919	79621396
Jaundice cholestatic	13.50	11.40	22	40051	11262	79693053
Musculoskeletal stiffness	13.50	11.40	44	40029	174964	79529351
Sleep disorder due to a general medical condition	13.39	11.40	25	40048	14252	79690063
Productive cough	13.35	11.40	83	39990	88248	79616067
Open reduction of fracture	13.34	11.40	5	40068	256	79704059
Ureteric obstruction	13.32	11.40	11	40062	2705	79701610
Kidney infection	13.21	11.40	32	40041	21819	79682496
Bladder irritation	13.14	11.40	5	40068	267	79704048
Joint swelling	13.11	11.40	88	39985	288558	79415757
Disease progression	13.11	11.40	48	40025	184314	79520001
Rash macular	13.08	11.40	38	40035	28861	79675454
Headache	13.07	11.40	425	39648	653347	79050968
Chest discomfort	13.04	11.40	116	39957	137928	79566387
Urine leukocyte esterase positive	13.03	11.40	13	40060	4078	79700237
Adverse event	13.02	11.40	7	40066	60207	79644108
Illness	12.97	11.40	52	40021	46459	79657856
Nephrolithiasis	12.85	11.40	57	40016	53234	79651081
Rhinitis	12.74	11.40	25	40048	14782	79689533
Oesophageal cancer metastatic	12.74	11.40	5	40068	290	79704025
Reperfusion arrhythmia	12.66	11.40	5	40068	295	79704020
Organising pneumonia	12.65	11.40	21	40052	10918	79693397
Subacute cutaneous lupus erythematosus	12.63	11.40	12	40061	3549	79700766
Urinary retention	12.49	11.40	59	40014	56571	79647744
Cholelithiasis	12.45	11.40	56	40017	52608	79651707
Vaginal discharge	12.45	11.40	17	40056	7446	79696869
Traumatic lung injury	12.39	11.40	10	40063	2381	79701934
Abdominal pain upper	12.33	11.40	169	39904	223650	79480665
Calculus bladder	12.30	11.40	8	40065	1364	79702951
Protein total abnormal	12.29	11.40	6	40067	589	79703726
Autoinflammatory disease	12.29	11.40	5	40068	319	79703996
Genital burning sensation	12.23	11.40	5	40068	323	79703992
Tracheo-oesophageal fistula	12.19	11.40	6	40067	600	79703715
Acarodermatitis	12.16	11.40	8	40065	1390	79702925
Duodenal ulcer	12.15	11.40	26	40047	16343	79687972
Completed suicide	12.15	11.40	73	40000	245694	79458621
Gait disturbance	11.97	11.40	158	39915	207348	79496967
Hepatitis cholestatic	11.45	11.40	23	40050	13829	79690486
Retroperitoneal fibrosis	11.43	11.40	6	40067	687	79703628
Hepatic enzyme increased	11.43	11.40	50	40023	182560	79521755

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01XE01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Nitrofuran derivatives
ATC	J01XE51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Nitrofuran derivatives
FDA CS	M0014892	Nitrofurans
FDA EPC	N0000175494	Nitrofuran Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000892	Anti-Infective Agents, Urinary
CHEBI has role	CHEBI:35441	antiinfective agents
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:50908	agente hepatotoxico

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Klebsiella cystitis	indication	60867007
Escherichia coli urinary tract infection	indication	301011002
Staphylococcus Saprophyticus Urinary Tract Infection	indication
Enterobacter Cystitis	indication
Enterococcus Urinary Tract Infection	indication
Staphylococcus Aureus Urinary Tract Infection	indication
Prevention of Bacterial Urinary Tract Infection	off-label use
Anuria	contraindication	2472002	DOID:2983
Acute hepatitis	contraindication	37871000
Vitamin B deficiency	contraindication	47903000
Fibrosis of lung	contraindication	51615001	DOID:3770
Obstructive hyperbilirubinemia	contraindication	59848001
Interstitial pneumonia	contraindication	64667001
Optic neuritis	contraindication	66760008	DOID:1210
Diabetes mellitus	contraindication	73211009	DOID:9351
Chronic hepatitis	contraindication	76783007	DOID:2237
Oliguria	contraindication	83128009
Cholestatic hepatitis	contraindication	95556007
Anemia due to enzyme deficiency	contraindication	111577008
Deficiency of glucose-6-phosphate dehydrogenase	contraindication	124134002	DOID:2862
Cobalamin deficiency	contraindication	190634004
Impaired renal function disorder	contraindication	197663003
Drug-induced hepatitis	contraindication	235876009
Peripheral nerve disease	contraindication	302226006
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.28	acidic
pKa2	0.0	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Glucose-6-phosphate 1-dehydrogenase	Enzyme	P11413	G6PD_HUMAN				WOMBAT-PK
CDGSH iron-sulfur domain-containing protein 1	Unclassified	Q9NZ45	CISD1_HUMAN		Ki	6.09	CHEMBL
Mitochondrial pyruvate carrier 2	Transporter	O95563	MPC2_HUMAN	INHIBITOR	IC50	5.48	IUPHAR

External reference:

ID	Source
4018849	VUID
N0000147151	NUI
D00439	KEGG_DRUG
54-87-5	SECONDARY_CAS_RN
17140-81-7	SECONDARY_CAS_RN
4018848	VANDF
4018849	VANDF
C0028156	UMLSCUI
CHEBI:71415	CHEBI
U6Z	PDB_CHEM_ID
CHEMBL572	ChEMBL_ID
DB00698	DRUGBANK_ID
CHEMBL1201000	ChEMBL_ID
D009582	MESH_DESCRIPTOR_UI
6604200	PUBCHEM_CID
10917	IUPHAR_LIGAND_ID
488	INN_ID
927AH8112L	UNII
221129	RXNORM
181427	MMSL
2320	MMSL
404	MMSL
5179	MMSL
5180	MMSL
5181	MMSL
d00112	MMSL
002852	NDDF
002853	NDDF
002854	NDDF
373543005	SNOMEDCT_US
37978007	SNOMEDCT_US
426476003	SNOMEDCT_US
427332002	SNOMEDCT_US
85343003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nitrofurantoin Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1643	CAPSULE	50 mg	ORAL	ANDA	25 sections
Nitrofurantoin Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1643	CAPSULE	50 mg	ORAL	ANDA	25 sections
Nitrofurantoin Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1645	CAPSULE	100 mg	ORAL	ANDA	25 sections
Nitrofurantoin Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1645	CAPSULE	100 mg	ORAL	ANDA	25 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-2023	CAPSULE	50 mg	ORAL	ANDA	25 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-2024	CAPSULE	100 mg	ORAL	ANDA	25 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0122	CAPSULE	25 mg	ORAL	ANDA	25 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0122	CAPSULE	25 mg	ORAL	ANDA	25 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0122	CAPSULE	75 mg	ORAL	ANDA	25 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0122	CAPSULE	75 mg	ORAL	ANDA	25 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0122	CAPSULE	75 mg	ORAL	ANDA	25 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0122	CAPSULE	25 mg	ORAL	ANDA	25 sections
Nitrofurantoin Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1866	CAPSULE	100 mg	ORAL	ANDA	26 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0472-1992	SUSPENSION	25 mg	ORAL	ANDA	19 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0480-3470	CAPSULE	75 mg	ORAL	ANDA	25 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0480-3470	CAPSULE	25 mg	ORAL	ANDA	25 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3684	CAPSULE	25 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3684	CAPSULE	25 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3685	CAPSULE	50 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3685	CAPSULE	50 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3686	CAPSULE	100 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3686	CAPSULE	100 mg	ORAL	ANDA	21 sections
nitrofurantoin macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7025	CAPSULE	100 mg	ORAL	ANDA	13 sections
nitrofurantoin macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7026	CAPSULE	50 mg	ORAL	ANDA	13 sections
nitrofurantoin macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7026	CAPSULE	50 mg	ORAL	ANDA	13 sections
nitrofurantoin macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7136	CAPSULE	100 mg	ORAL	NDA	25 sections
Nitrofurantoin Monohydrate/ Macrocrystalline	HUMAN PRESCRIPTION DRUG LABEL	2	0904-7137	CAPSULE	75 mg	ORAL	NDA	27 sections
Nitrofurantoin Monohydrate/ Macrocrystalline	HUMAN PRESCRIPTION DRUG LABEL	2	0904-7137	CAPSULE	25 mg	ORAL	NDA	27 sections
Nitrofurantoin Monohydrate/ Macrocrystalline	HUMAN PRESCRIPTION DRUG LABEL	2	10544-086	CAPSULE	25 mg	ORAL	NDA	28 sections
Nitrofurantoin Monohydrate/ Macrocrystalline	HUMAN PRESCRIPTION DRUG LABEL	2	10544-086	CAPSULE	75 mg	ORAL	NDA	28 sections